ClinicalTrials.gg
Active, not recruitingNCT06018558ArMaDaUpdated Nov 10, 2026

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

A Phase 1/2 interventional study of OCU410 in Geographic Atrophy, sponsored by Ocugen. Active, not recruiting at 12 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Ocugen · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 10, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
65th of 107
60 · median 98
Started
2023
with 11 others
Phase 1/2
17 of 131
7 open now
Primary completion
2026-02
later than 5 of 44 live
Registered
90th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 65th largest by enrollment of the 107 interventional ones that give a count, is one of 12 that started in 2023, is one of 17 in phase 1/2, reaches primary completion later than 5 of the 44 other live ones, and was the 90th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD).

This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 60 subjects.

Read the detailed description

Name of Sponsor/Company:

Ocugen, Inc. 11 Great Valley Parkway Malvern, PA 19355

Name of Investigational Product: OCU410

Name of Active Ingredient:

Adeno-associated viral vector 5 human RORA (AAV5-hRORA) Protocol Number: OCU410-101 Phase: 1/2 Country: US

Title of Study:

A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration.

Study Center(s): Approximately 14 clinical study centers in the US.

Background:

Age-related Macular Degeneration (AMD) is an ocular disease where macular degenerative occurs. AMD manifests in two forms, Dry (nonexudative, atrophic) AMD and Wet (exudative, neovascular) AMD. Geographic atrophy (GA) is an advanced stage of dry AMD that affects nearly 1 million people in the US and 5 million people worldwide, with its prevalence increasing exponentially with age. It leads to progressive and irreversible loss of visual function due to the growth of atrophic lesions that destroy the retinal cells responsible for vision.

OCU410 Product Information:

Ocugen, Inc., has developed a proprietary modifier gene therapy platform, OCU410, as the second agent in a novel class of NHR-based gene modifier therapy for patients with dry AMD. The proposed indication for OCU410 (AAV5-hRORA) is for the treatment of GA secondary to dry AMD. The drug product is a sterile ophthalmic suspension for subretinal injection. OCU410 therapy regulates gene pathways contributing to GA by restoring homeostasis in the eye and thereby serving as a therapeutic candidate for dry AMD. The modifier gene therapy platform is a new way of addressing a genetic disease arising through a multitude of genetic mutations in various genes but leading to the same end result (phenotype) of a diseased condition.

This study will be conducted in two phases enrolling up to 60 subjects. Treated subjects will receive a single subretinal injection of OCU410 in the study eye.

Phase 1 is a multicenter, open-label, dose-ranging/dose-escalating study with a 3+3 design enrolling 9 subjects.

Phase 2 is a dose-expansion phase of the study, where up to 51 subjects will be randomized in 1:1:1 ratio to either two OCU410 dose groups (n=17 per group) or to an untreated control group (n=17).

.

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects 50 years of age or older.
  2. BCVA of approximately 21 letters or more using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (20/320 Snellen equivalent).
  3. Fundus autofluorescence (FAF) imaging shows:

    1. Total GA area ≥2.0 and ≤20.5 mm2 (1 and 8 disk areas [DA], respectively)
    2. If GA is multifocal, at least one focal lesion must be ≥1.25 mm2 (0.5 DA), with the overall aggregate area of GA as specified above in 3.a
    3. The entire GA lesion must be completely visualized on the macula-centered image and must be able to be imaged in its entirety, and not contiguous with any areas of peripapillary atrophy
    4. Presence of any pattern of hyper-autofluorescence in the junctional zone of GA
  4. Subjects who had prior treatment with an approved drug for AMD, e.g. Izerway® (Avacincaptad pegol) or Syfovre® (Pegcetacoplan injection) can be included, after a of at least 3 months in study eye. Subjects can receive an approved drug for AMD in the fellow eye, if required.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with a gene-therapy or cell therapy product
  2. GA due to causes other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like Plaquenil maculopathy. However, benign conditions of the vitreous or peripheral retina are not exclusionary (i.e., pavingstone degeneration).
  3. Spherical equivalent of the refractive error demonstrating > 6 diopters of myopia or an axial length >26 mm, inability to fixate, uncontrolled glaucoma, advanced cataract, corneal abnormalities, medium haze, and other retinal pathologies.
  4. Any history or current evidence of exudative ("wet") AMD including any evidence of retinal pigment epithelium rips, branch retinal artery or vein occlusion, corneal transplant, or evidence of neovascularization anywhere in the retina based on fluorescein angiogram.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Phase1 Dose Escalation- Low Dose (2.5×10E10 vg/mL):

    Low Dose (2.5×10E10 vg/mL): Subjects will receive a subretinal injection of OCU410 in the low dose concentration.

    Genetic: OCU410

  • Experimental
    Phase1 Dose Escalation- Medium Dose (5×10E10 vg/mL):

    Medium Dose (5×10E10 vg/mL): Subjects will receive a subretinal injection of OCU410 in the medium dose concentration.

    Genetic: OCU410

  • Experimental
    Phase1 Dose Escalation- High Dose (1.5×10E11 vg/mL):

    High Dose (1.5×10E11 vg/mL): Subjects will receive a subretinal injection in the high dose concentration.

    Genetic: OCU410

  • Experimental
    Phase 2 Dose Expansion: Maximum tolerated dose (MTD) from Phase 1-Randomized Arm

    Maximum tolerated dose (MTD) from Phase 1: Subjects will receive a subretinal injection in the MTD concentration.

    Genetic: OCU410

  • Experimental
    Phase 2 Dose Expansion: Lower Dose from Phase 1-Randomized Arm

    Subjects will receive a subretinal injection of OCU410 in a Lower Dose concentration.

    Genetic: OCU410

  • No intervention
    Control Arm

    No Intervention Control Arm: Subject will not receive any active study intervention

Interventions

  • GeneticOCU410

    Subretinal administration of OCU410

06

What researchers measure

Primary outcomes

  1. Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))

    The primary endpoint is safety, determined by the number of ocular and non-ocular Study Drug-related adverse events (SDAE), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  2. Change in anatomy of ocular structures using Slit Lamp Biomicroscopy

    We will use Slit-lamp Biomicroscopy to visualize the anatomy of ocular structures before and after sub-retinal injections and follow-up visits.

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  3. Change in anatomy of ocular structures using Indirect ophthalmoscopy

    We will use Indirect ophthalmoscopy to visualize the anatomy of ocular structures before and after sub-retinal injections and follow-up visits.

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  4. Change from baseline in BCVA (Best Corrected Visual Acuity)

    Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision.

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  5. Change in Low Luminance Visual Acuity

    Measured by letter score. A higher score represents better vision

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  6. Change in the Intraocular Pressure (mmHg)

    Measured by applanation or rebound tonometry with confirmation with Goldmann tonometer if IOP is outside normal range (8-21mmHg).

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

Secondary outcomes

  1. Humoral and cellular immune response

    Blood samples will be collected for the assessment. The secondary safety endpoints include change from baseline in Humoral and cellular immune response in response to OCU410 administration

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  2. Shedding of viral vector

    Blood samples will be collected for the assessment to determine AAV vector shedding in systemic circulation after OCU410 administration

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  3. Laboratory parameters including serum chemistry and hematology

    Blood samples will be collected for the assessment to determine a change from baseline after OCU410 administration.

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

Other outcomes

  1. Structural Outcome: Change Using Qualitative and quantitative assessments of autofluorescence pattern (FAF)

    Changes in the intensity of FAF will be evaluated from the baseline measurements, to assess the loss of retinal layers.

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  2. Changes in National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ25)

    The National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ25) questionnaires will be completed to assess the impact of vision on quality of subject's life.

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  3. Change From Baseline in Mean Threshold Sensitivity (MAIA)

    Mean threshold sensitivity of all points will be determined to assess the macular functional response and determine GA progression.

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  4. Change from Baseline in drusen volume using SD-OCT

    Measurement of change in drusen volume will be determined using Spectral Domain OCT measurements.

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

  5. Change from Baseline in Exploratory Structural Imaging parameters including EZ and RPE loss

    Measurement of change in structural parameters will be determined using imaging from Spectral Domain OCT measurements.

    Time frame: 12 months (Screening to 12 months post OCU410 administration)

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified participant data will be made available to qualified researchers on reasonable request to the sponsor (Ocugen, Inc.), after publication of the study results, subject to a data use agreement.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Will be available pending publication of results from Phase 1 and Phase 2 trials in a peer reviewed publication

Access criteria: Upon written request to the sponsor

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2023 to primary completion in Feb 2026, 27 months.

Start moved once since we started tracking on Sep 25, 2026: Feb 2023 → Oct 2023, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Aug 30, 2023
StartActual
Oct 27, 2023was Feb 2023
Primary completionActual
Feb 3, 2026
CompletionEst.
Feb 3, 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 23, 2023→Oct 27, 2023
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Start date Feb 23, 2023→Oct 27, 2023
    + 1 other change: verification date
  2. Oct 30, 2026
    Minor edits only
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06018558
Lead sponsor
Ocugen
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Oct 27, 2023
Primary completion
Feb 3, 2026
Completion
Feb 3, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Jennifer Henrick, RN, MS
study director · Ocugen., Inc.
Mohamed Genead, MD
study chair · Ocugen., Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion